ALK-Abello revises upward financial outlook for 2019.

NORDIC BUSINESS REPORT-August 13, 2019-ALK-Abello revises upward financial outlook for 2019

(C)2019 M2 COMMUNICATIONS http://www.m2.com

ALK Abello A/S (ALK) (CPH:ALKB), a global specialty pharmaceutical company focused on allergy and allergic asthma, announced on Monday the revision of its 2019 financial guidance upwards based on the better than expected results in the first half-year and the forecast for the second half-year.

Under this revision, full-year revenues for 2019 is now projected to be DKK3,200m to DKK3,300m, as compared with the prior outlook of DKK3,100m to DKK3,300m.

Operating profit (EBITDA) for 2019 is now expected at DKK150m to DKK250m, as compared with the prior DKK 100m to DKK200m.

According to the company, this revenue update...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT